Literature DB >> 15946252

Integrin CD11a cytoplasmic tail interacts with the CD45 membrane-proximal protein tyrosine phosphatase domain 1.

Xin Geng1, Ren-Hong Tang, S K Alex Law, Suet-Mien Tan.   

Abstract

Leucocyte adhesion receptor integrin CD11aCD18 and the transmembrane receptor-like protein tyrosine phosphatase (RPTP) CD45 mediate immune synapse formation and signalling during antigen presentation. Previous cocapping studies on human naïve T cells demonstrate an interaction between CD11aCD18 and CD45. CD45 cross-linking also has an effect on the ligand-binding activity of CD11aCD18. However, the mode of interaction between CD11aCD18 and CD45 remains unclear. Herein, yeast two-hybrid analysis identified a partial CD45 cytoplasmic tail interacting with that of CD11a. The CD45 cytoplasmic tail comprises a membrane proximal (Mp) region, protein tyrosine phosphatase domain 1 (D1), spacer, D2, and carboxyl terminus. CD45 Mp-D1 was found to be the main interacting region for the CD11a cytoplasmic tail. In contrast, the full-length CD45 cytoplasmic tail interacted weakly with that of CD11a. It has been reported that CD45 Mp-D1 but not the full-length cytoplasmic tail forms a homodimer whose enzymatic activity is inhibited. Our in vitro binding and enzymatic assays showed that the homodimeric CD45 cytoplasmic tail interacts with that of CD11a. The biological function of CD45 dimerization and its association with CD11a remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15946252      PMCID: PMC1782157          DOI: 10.1111/j.1365-2567.2005.02175.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  44 in total

1.  Intra- and intermolecular interactions of the catalytic domains of human CD45 protein tyrosine phosphatase.

Authors:  K Hayami-Noumi; T Tsuchiya; Y Moriyama; T Noumi
Journal:  FEBS Lett       Date:  2000-02-18       Impact factor: 4.124

2.  CD45 function is regulated by an acidic 19-amino acid insert in domain II that serves as a binding and phosphoacceptor site for casein kinase 2.

Authors:  S F Greer; Y Wang ; C Raman; L B Justement
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

3.  Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms.

Authors:  Zheng Xu; Arthur Weiss
Journal:  Nat Immunol       Date:  2002-07-22       Impact factor: 25.606

Review 4.  CD45: new jobs for an old acquaintance.

Authors:  J M Penninger; J Irie-Sasaki; T Sasaki; A J Oliveira-dos-Santos
Journal:  Nat Immunol       Date:  2001-05       Impact factor: 25.606

5.  CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling.

Authors:  J Irie-Sasaki; T Sasaki; W Matsumoto; A Opavsky; M Cheng; G Welstead; E Griffiths; C Krawczyk; C D Richardson; K Aitken; N Iscove; G Koretzky; P Johnson; P Liu; D M Rothstein; J M Penninger
Journal:  Nature       Date:  2001-01-18       Impact factor: 49.962

6.  Specific activation of leukocyte beta2 integrins lymphocyte function-associated antigen-1 and Mac-1 by chemokines mediated by distinct pathways via the alpha subunit cytoplasmic domains.

Authors:  K S Weber; L B Klickstein; C Weber
Journal:  Mol Biol Cell       Date:  1999-04       Impact factor: 4.138

7.  A deletion in the gene encoding the CD45 antigen in a patient with SCID.

Authors:  E Z Tchilian; D L Wallace; R S Wells; D R Flower; G Morgan; P C Beverley
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

8.  Receptor-like protein tyrosine phosphatase alpha homodimerizes on the cell surface.

Authors:  G Jiang; J den Hertog; T Hunter
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

9.  Effect of integrin beta 2 subunit truncations on LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) assembly, surface expression, and function.

Authors:  S M Tan; R H Hyland; A Al-Shamkhani; W A Douglass; J M Shaw; S K Law
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

10.  CD45 negatively regulates monocytic cell differentiation by inhibiting phorbol 12-myristate 13-acetate-dependent activation and tyrosine phosphorylation of protein kinase Cdelta.

Authors:  E L Deszo; D K Brake; K A Cengel; K W Kelley; G G Freund
Journal:  J Biol Chem       Date:  2000-12-21       Impact factor: 5.157

View more
  6 in total

1.  Structures and interaction analyses of integrin αMβ2 cytoplasmic tails.

Authors:  Geok-Lin Chua; Xiao-Yan Tang; Monalisa Amalraj; Suet-Mien Tan; Surajit Bhattacharjya
Journal:  J Biol Chem       Date:  2011-11-03       Impact factor: 5.157

2.  Integrin alpha4beta1 promotes focal adhesion kinase-independent cell motility via alpha4 cytoplasmic domain-specific activation of c-Src.

Authors:  Datsun A Hsia; Ssang-Taek Lim; Joie A Bernard-Trifilo; Satyajit K Mitra; Sakae Tanaka; Jeroen den Hertog; Daniel N Streblow; Dusko Ilic; Mark H Ginsberg; David D Schlaepfer
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

3.  Dynamic regulation of CD45 lateral mobility by the spectrin-ankyrin cytoskeleton of T cells.

Authors:  Christopher W Cairo; Raibatak Das; Amgad Albohy; Quentin J Baca; Deepti Pradhan; Jon S Morrow; Daniel Coombs; David E Golan
Journal:  J Biol Chem       Date:  2010-02-17       Impact factor: 5.157

4.  Distinct FAK-Src activation events promote alpha5beta1 and alpha4beta1 integrin-stimulated neuroblastoma cell motility.

Authors:  L Wu; J A Bernard-Trifilo; Y Lim; S-T Lim; S K Mitra; S Uryu; M Chen; C J Pallen; N-Kv Cheung; D Mikolon; A Mielgo; D G Stupack; D D Schlaepfer
Journal:  Oncogene       Date:  2007-09-10       Impact factor: 9.867

5.  Combinations of CD45 isoforms are crucial for immune function and disease.

Authors:  Ritu Dawes; Svetla Petrova; Zhe Liu; David Wraith; Peter C L Beverley; Elma Z Tchilian
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

6.  Structure and binding interface of the cytosolic tails of αXβ2 integrin.

Authors:  Geok-Lin Chua; Xiao-Yan Tang; Alok Tanala Patra; Suet-Mien Tan; Surajit Bhattacharjya
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.